HER2 –OtherPrint this page
Updated Test Information:
Probes: HER2(17q12)/CEP 17 (17p11.2)
Disease(s): Endometrial cancer, salivary duct carcinoma, ovarian cancer, serous carcinomas and other various tumor types.
Formalin fixed paraffin embedded (FFPE) tissue blocks or
|Additional Processing Details||
Transport to the testing lab at room temp is acceptable. Do not allow sample to overheat. Use cold pack for transport, making sure cold pack is not in direct contact with specimen
Complete the Incyte Diagnostics hematology requisition with the patient's demographics and relevant clinical history. Label the specimen containers with patient's full name, second unique identifier, and specimen site/source.
|Unacceptable Specimen Conditions||
Specimen containers without two (2) patient identifiers, specimens submitted on non-positively charged slides, paraffin blocks that have been overheated or frozen, specimens without a H&E slide, slides or paraffin blocks with no tissue remaining, Samples fixed in fixative other than 10% neutral buffered formalin.
Fluorescence in-Situ Hybridization (FISH)
3-5 working days from receipt
Clinical Significance: HER2, a member of the epidermal growth factor receptor family, is a transmembrane protein with tyrosine kinase activity. Gene amplification and protein overexpression of HER2 have been found in a variety of tumors. This test provides HER2 amplification status to aid in determining anti-HER2 targeted therapies for patients. Scoring is performed using the following:
HER2 (Other) with Breast scoring uses the 2018 CAP/ASCO guidelines for breast cancer for HER2 evaluation. Breast scoring is recommended for indications such as endometrium cancer, salivary duct carcinoma, serous carcinoma, and ovarian cancer as well as other clinical indications without consensus guidelines.